GO
Loading...

Merck & Co Inc

More

  • Wall St. to read economic tea leaves from Fed, GDP Tuesday, 29 Jul 2014 | 5:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    Wall Street on Wednesday will get two reads on the U.S. economy, one from the Commerce Department and the other from the Federal Reserve.

  • July 29- Pfizer Inc, which in May abandoned its $118 billion bid to buy AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. Under UK takeover rules, AstraZeneca can attempt to re-engage with Pfizer in August, and Pfizer can make another run at AstraZeneca in November.

  • July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading.

  • Merck & Pfizer beat the Street     Tuesday, 29 Jul 2014 | 10:14 AM ET

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • Merck CEO to CNBC: US tax system broken     Tuesday, 29 Jul 2014 | 9:40 AM ET

    CNBC's Meg Tirrell spoke with Merck CEO Ken Frazier after earnings. Frazier spoke about the competition in hepatitis C, industry consolidation and shared his opinions on the U.S. tax system.

  • Cramer: Stay long Merck     Tuesday, 29 Jul 2014 | 9:06 AM ET

    The "Squawk on the Street" news team discusses the quarterly results of Merck and Pfizer.

  • Stock futures further their rise on home-price data Tuesday, 29 Jul 2014 | 9:05 AM ET

    U.S. stock-index futures rose Tuesday as investors looked to economic reports, earnings and the Fed's mid-week policy decision.

  • July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, with sales of consumer products and medicines for arthritis and HIV helping to offset the impact of generic competition on other drug sales. Merck, the No. 2 U.S. drugmaker, earned $2.03 billion, or 68 cents per share, in the second quarter.

  • 'This bull market has more legs': Pro Tuesday, 29 Jul 2014 | 8:53 AM ET

    Stronger earnings for the second quarter and beyond will be the key driver that keeps gas in the bull market gas tank, leading quantitative strategists tell CNBC.

  • Big pharma tax attack     Tuesday, 29 Jul 2014 | 8:04 AM ET

    Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.

  • Big pharma by the numbers     Tuesday, 29 Jul 2014 | 8:02 AM ET

    What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.

  • Early movers: UPS, MRK, PFE, MCD, DRI, HLF & more Tuesday, 29 Jul 2014 | 7:47 AM ET

    Some of the names on the move ahead of the open.

  • Merck 2Q profit more than doubles Tuesday, 29 Jul 2014 | 7:28 AM ET

    The maker of popular Type 2 diabetes pill Januvia said Tuesday that net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

  • Stocks end lower ahead of economic data Tuesday, 29 Jul 2014 | 3:37 AM ET

    Major indexes in Europe and Asia closed with slight gains. On Friday, the Labor Department releases its monthly look at the job market. FROZEN: "The market today looks a little frozen, because it's going to face some really revealing stuff in the next 72 hours," said Jim Paulsen, chief investment strategist at Wells Capital Management.

  • Why the Fed could raise rates sooner than you think Monday, 28 Jul 2014 | 4:36 PM ET
    Federal Reserve Board Chairwoman Janet Yellen testifies before the Senate Banking, Housing and Urban Affairs Committee July 15, 2014, in Washington.

    The Fed meets for two days, starting Tuesday, and is widely expected to taper back its monthly bond buying program by another $10 billion to $25 billion - and do little else.

  • Business events scheduled for Tuesday Monday, 28 Jul 2014 | 2:10 PM ET

    WASHINGTON— Standard& Poor's releases S&P/Case-Shiller index of home prices for May, 9 a.m.. WASHINGTON— The Conference Board releases the Consumer Confidence Index for July, 10 a.m.. WASHINGTON— House Energy and Commerce subcommittee hearing on EPA's proposed clean power plan and grid reliability challenges.

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • Summer's busiest week for markets is here Friday, 25 Jul 2014 | 6:10 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.